Skip to main content

Table 3 Results of PET/CT parameters in relation to pathologic response (n = 25)

From: Predicting pathological response of locally advanced breast cancer to neoadjuvant chemotherapy: comparing the performance of whole body 18F-FDG PETCT versus DCE-MRI of the breast

  pCR (n = 8) Non-pCR (n = 17) p value
Median (Range) Median (range)
PET/CT Initial      
SUV max 8.8 (5.4–16.0) 5.7 (2.1–12.9) 0.027
SUV mean 4.9 (2.7–5.7) 2.7 (1.1–6.2) 0.016
MTV 19.3 (2.4–32.0) 20.8 (5.1–128.1) 0.406
TLG 96.9 (8.7–166.4) 61.4 (9.7–584.5) 0.798
PET/CT Interim      
SUV max 2.9 (1.4–16.0) 2.5 (1.0–7.4) 0.581
SUV mean 1.9 (1.0–10.2) 1.8 (0.7–4.0) 0731
MTV 5.2 (1.2–15.5) 7.4 (1.1–32.4) 0.407
TLG 6.1 (1.2–86.7) 17.6 (2.8–198.9) 0.490
PET/CT (baseline vs interim)      
SUVmax regression % 70.5 (0.0–100.0) 52.0 (25.0–100.0) 0.754
SUVmean regression % 60.0 (96.2–100.0) 39.3 (0.0–84.0) 0.157
MTV % change 79.0 (47.0–100.0) 73.0 (5.0–100.0) 0.440
TLG regression % 86.0 (47.0–100.0) 82.0 (23.0–100.0) 0.588
  1. Bold means the parameter was significant p-value < 0.05